|
 |
|
|
|
BioGeneric Pharma recognizes the role of
biotechnology as the future of the global pharmaceutical industry in enhancing
therapeutic effectiveness, improving lifestyle quality and strengthening
corporate profitability. In view of this, the company is involved in the
creation of significant biotechnology capabilities & capacities especially
in the area of protein processing solutions to provide services for the biotech
& pharmaceutical companies.
With the goal of developing a robust clinical pipeline containing multiple
novel drug molecules in different stages of clinical development, a large
number of discovery-stage and clinical development stage programs have been
strategically planned. Powerful discovery infrastructure that combines
world-class biology in important disease pathways with functionally integrated
chemistry capabilities drives our programs.
Our list of products in the pipe line includes:
- PEG-Filgrastim
- PEG-Interferon alfa 2a
- PEG-Interferon alfa 2b
- PEG-Somatropin
- PEG-Erythropoietin
|
|
 |
|
|
|
|
|
